Skip to main content

Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. is an American clinical-stage biopharmaceutical company developing RNA interference (RNAi) therapeutics. The company utilizes its proprietary Targeted RNAi Molecule (TRiM) platform to silence disease-causing genes across liver, pulmonary, and cardiometabolic disorders. Its clinical pipeline features RNAi therapeutic candidates targeting hypertriglyceridemia, hepatitis B, amyloidosis, and cardiovascular conditions. Primary revenue drivers are biopharmaceutical collaboration milestone payments, upfront licensing fees, and research funding from pharmaceutical partners. Arrowhead Pharmaceuticals holds a market-leading position in RNAi drug delivery technology. The company is headquartered in Pasadena, California, and its shares trade on the Nasdaq Global Select Market.

12 of the funds FundTelligence covers report a position in Arrowhead Pharmaceuticals.

Legal name
Arrowhead Pharmaceuticals Inc
Sector
Health Care
Country
United States
Funds holding it
12
Exposure themes
Genetic Medicine, Precision Medicine & Genomics, RNA Therapeutics

Funds holding Arrowhead Pharmaceuticals

Showing the 8 largest of 12 funds holding it.

Loading...